Skip to main content
. 2025 Sep 3;16:1648083. doi: 10.3389/fendo.2025.1648083

Table 2.

Differential mortality in stage 3 CKM: competing risks of CKD-dominant vs. CVD-dominant phenotypes.

Onset age (years) Control subjects Case subjects Hazard ratio (95% CI) P value
Event/Total Rate Event/Total Rate
New-onset CKM syndrome Stage 3 with very high-risk CKD (P for interaction = 0.009)
<45 4/1070 0.45 7/1002 0.83 2.39 (0.59 - 9.71) 0.224
45-54 37/951 4.08 46/483 10.63 3.25 (2.06 - 5.13) <0.001
55-64 263/3421 8.93 98/511 22.32 2.92 (2.28 - 3.74) <0.001
≥65 1442/5924 30.26 106/288 46.29 1.96 (1.60 - 2.41) <0.001
New-onset CKM syndrome Stage 3 with high predicted CVD risk (P for interaction < 0.001)
<45 4/1070 0.45 7/68 11.77 24.06 (3.94 - 146.92) <0.001
45-54 37/951 4.08 57/476 12.70 2.82 (1.80 - 4.41) <0.001
55-64 263/3421 8.93 370/2954 14.98 1.66 (1.41 - 1.97) <0.001
≥65 1442/5924 30.26 1507/5723 31.99 1.01 (0.93 - 1.09) 0.836

Data presented as hazard ratio (95% confidence interval), with event rates per 100 person-years.

P values for phenotype-age interaction terms: very high-risk CKD cohort = 0.009, high predicted CVD risk cohort < 0.001. Control subjects: Age-matched individuals without cardio-kidney-metabolic dysfunction. Case subjects: New-onset Stage 3 CKM patients stratified by predominant phenotype.